About Obalon Therapeutics (NASDAQ:OBLN)
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBLN
CUSIPN/A
Phone760-795-6558
Debt
Debt-to-Equity Ratio0.23%
Current Ratio5.17%
Quick Ratio5.03%
Price-To-Earnings
Trailing P/E Ratio-1.72
Forward P/E Ratio-1.86
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.91 million
Price / Sales6.59
Cash FlowN/A
Price / CashN/A
Book Value$1.54 per share
Price / Book2.42
Profitability
EPS (Most Recent Fiscal Year)($2.08)
Net Income$-34,760,000.00
Net Margins-350.67%
Return on Equity-74.80%
Return on Assets-56.13%
Miscellaneous
Employees113
Outstanding Shares17,560,000
Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therapeutics' stock symbol?
Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."
How were Obalon Therapeutics' earnings last quarter?
Obalon Therapeutics Inc. (NASDAQ:OBLN) announced its quarterly earnings results on Monday, March, 5th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.12. The firm had revenue of $3.69 million for the quarter, compared to analysts' expectations of $3.88 million. Obalon Therapeutics had a negative net margin of 350.67% and a negative return on equity of 74.80%. View Obalon Therapeutics' Earnings History.
When is Obalon Therapeutics' next earnings date?
What price target have analysts set for OBLN?
5 brokerages have issued 1-year target prices for Obalon Therapeutics' shares. Their forecasts range from $4.00 to $16.00. On average, they anticipate Obalon Therapeutics' stock price to reach $9.25 in the next twelve months. View Analyst Ratings for Obalon Therapeutics.
What are Wall Street analysts saying about Obalon Therapeutics stock?
Here are some recent quotes from research analysts about Obalon Therapeutics stock:
- 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (4/20/2018)
- 2. Northland Securities analysts commented, "We have reached out to management, but have not heard back yet. As we have said multiple times in our notes, we are persona non grata with the company, hence are not hopeful that we can have adequate answers to our questions, which are: What specifically is the allegation? Is it about channel stuffing? Is it about revenue recognition? As highlighted in our Dec 6, 2017 research note, we had questions about Obalon’s revenue recognition criteria, and how the accounting for deliverables was being done. A key question for us is…who knew what & when? Is there any truth to the whistleblower allegations, whatever they may be? As a reminder, Obalon’s new marketing program was implemented at start of Q4-17." (1/23/2018)
- 3. BTIG Research analysts commented, "Agreements, Navigation, and Market Growth We hosted CEO Andy Rasdal and CFO Bill Plovanic for a series of investor meetings. Overall, management remained upbeat about the long-term opportunity, underpinned by the recently announced agreement with Sono Bello (Private) and potential incremental revenue stream afforded by the yet-to-be approved navigation system. Sono Bello adds a sizable aesthetic practice to existing customer base. OBLN’s agreement with Sono Bello is important for a variety of reasons. First, the agreement provides a significant boost to the account base (40+ locations, 100+ physicians) and adds a focus from Sono Bello to offer a novel weight loss solution. Second, the agreement will help with other potential plastic surgeon customers who may look to Sono Bello for indications of patient interest. We expect Sono Bello to roll OBLN out in stages as it figures out how best to offer balloons and also benefit its own liposuction practice. Navigation, while still not FDA cleared, removes a barrier to entry. Mgmt. provided incremental details on the navigation system including expectations to be substantially less expensive than X-Ray. We believe the Navigation system may be approved in 1H18 as PMA supplements usually take approximately 6 months and it has been submitted." (11/16/2017)
Who are some of Obalon Therapeutics' key competitors?
Some companies that are related to Obalon Therapeutics include Cytosorbents (CTSO), Nuvectra (NVTR), SeaSpine (SPNE), IRadimed (IRMD), Restoration Robotics (HAIR), Apollo Endosurgery (APEN), Alphatec (ATEC), INVO Bioscience (IVOB), Invuity (IVTY), Sensus Healthcare (SRTS), Motus GI (MOTS), SANUWAVE (SNWV), Neovasc (NVCN), iCAD (ICAD) and Spectral Medical (EDTXF).
Who are Obalon Therapeutics' key executives?
Obalon Therapeutics' management team includes the folowing people:
- Mr. Andrew P. Rasdal, Pres, CEO & Director (Age 60)
- Mr. William John Plovanic CFA, CFO & Sec. (Age 49)
- Mr. Mark C. Brister, Chief Technology Officer (Age 56)
- Dr. Kelly Huang Ph.D., Chief Operating Officer (Age 49)
- Ms. Nooshin Hussainy, VP of Fin. & Principal Accounting Officer (Age 60)
When did Obalon Therapeutics IPO?
(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.
Has Obalon Therapeutics been receiving favorable news coverage?
News headlines about OBLN stock have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Obalon Therapeutics earned a daily sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 45.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Obalon Therapeutics?
Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obalon Therapeutics' stock price today?
One share of OBLN stock can currently be purchased for approximately $3.72.
How big of a company is Obalon Therapeutics?
Obalon Therapeutics has a market capitalization of $59.54 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.
How can I contact Obalon Therapeutics?
Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]
MarketBeat Community Rating for Obalon Therapeutics (OBLN)
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Obalon Therapeutics (NASDAQ:OBLN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Obalon Therapeutics in the last 12 months. Their average twelve-month price target is $9.25, suggesting that the stock has a possible upside of 148.66%. The high price target for OBLN is $16.00 and the low price target for OBLN is $4.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.50 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.25 | $9.25 | $11.50 | $16.20 |
| Price Target Upside: | 148.66% upside | 139.64% upside | 121.58% upside | 84.30% upside |
Obalon Therapeutics (NASDAQ:OBLN) Consensus Price Target History
Obalon Therapeutics (NASDAQ:OBLN) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Obalon Therapeutics (NASDAQ:OBLN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Obalon Therapeutics (NASDAQ OBLN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Obalon Therapeutics Inc. (OBLN) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 24 at 3:12 PM |
| Obalon Therapeutics (OBLN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 20 at 7:02 AM |
| AtriCure (ATRC) vs. Obalon Therapeutics (OBLN) Head-To-Head Survey
www.americanbankingnews.com - April 17 at 1:52 AM |
 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 16 at 4:14 PM |
| DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 13 at 4:18 PM |
| Obalon Therapeutics (OBLN) Rating Reiterated by UBS
www.americanbankingnews.com - April 13 at 1:00 PM |
| April 16th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Obalon Therapeutics, Inc. (OBLN)
finance.yahoo.com - April 13 at 10:09 AM |
| Obalon Therapeutics (OBLN) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 12 at 9:35 PM |
| Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Obalon Therapeutics, Inc. (OBLN) and April 16 Lead Plaintiff Deadline
finance.yahoo.com - April 12 at 4:16 PM |
| 4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 12 at 4:16 PM |
| Obalon Therapeutics' (OBLN) Buy Rating Reaffirmed at UBS
www.americanbankingnews.com - April 12 at 3:58 PM |
| Glancy Prongay & Murray LLP Reminds Investors of the April 16, 2018 Deadline in the Class Action Lawsuit Against Obalon Therapeutics, Inc. (OBLN)
finance.yahoo.com - April 11 at 10:22 AM |
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline - April 16, 2018
finance.yahoo.com - April 11 at 10:22 AM |
| 6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 10 at 4:17 PM |
 | Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the Firm ...
www.businesswire.com - April 10 at 10:07 AM |
| Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the Firm Before April 16th
finance.yahoo.com - April 10 at 10:07 AM |
| FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Obalon Therapeutics, Inc. (Nasdaq: OBLN) To Contact The Firm
finance.yahoo.com - April 9 at 4:15 PM |
| APRIL 16 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 9 at 4:15 PM |
| $3.55 Million in Sales Expected for Obalon Therapeutics Inc. (OBLN) This Quarter
www.americanbankingnews.com - April 9 at 2:34 AM |
| DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 7 at 5:17 PM |
| IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. And Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 5 at 4:16 PM |
| Obalon Therapeutics (OBLN) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM |
| Obalon Therapeutics Inc. (OBLN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 3:26 AM |
| IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. And Reminds Investors to ContactThe Firm
finance.yahoo.com - March 31 at 4:14 PM |
| Obalon Therapeutics (OBLN) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:00 AM |
| Obalon Therapeutics (OBLN) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - March 27 at 10:01 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Obalon Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – OBLN
finance.yahoo.com - March 25 at 10:00 AM |
| $3.55 Million in Sales Expected for Obalon Therapeutics Inc (OBLN) This Quarter
www.americanbankingnews.com - March 23 at 4:00 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline - April 16, 2018
finance.yahoo.com - March 22 at 4:13 PM |
| OBLN NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. - OBLN
finance.yahoo.com - March 22 at 4:13 PM |
| Neil Drake Acquires 5,000 Shares of Obalon Therapeutics Inc (OBLN) Stock
www.americanbankingnews.com - March 19 at 8:30 PM |
| With A -69.86% Earnings Drop, Did Obalon Therapeutics Inc (NASDAQ:OBLN) Really Underperform?
finance.yahoo.com - March 17 at 9:56 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline: April 16, 2018
finance.yahoo.com - March 16 at 5:11 PM |
| DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Obalon Therapeutics, Inc. to Contact the Firm
finance.yahoo.com - March 16 at 5:11 PM |
| Obalon Therapeutics Inc (OBLN) CFO William J. Plovanic Acquires 30,000 Shares
www.americanbankingnews.com - March 15 at 10:26 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Obalon Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OBLN
finance.yahoo.com - March 15 at 9:37 AM |
| INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc.
finance.yahoo.com - March 8 at 5:05 PM |
| Obalon Therapeutics (OBLN) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 8 at 7:29 AM |
| Obalon Therapeutics Inc (OBLN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 7 at 3:44 AM |
| Obalon Therapeutics' (OBLN) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - March 6 at 8:36 PM |
| Obalon Therapeutics (OBLN) Price Target Lowered to $7.00 at BTIG Research
www.americanbankingnews.com - March 6 at 7:30 PM |
| Obalon Therapeutics' (OBLN) Buy Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - March 6 at 2:35 PM |
| Tamarack Advisers LP Has $3.99 Million Position in Obalon Therapeutics Inc (OBLN)
www.americanbankingnews.com - March 6 at 10:30 AM |
| Obalon Therapeutics (OBLN) Releases Earnings Results, Misses Expectations By $0.12 EPS
www.americanbankingnews.com - March 6 at 8:24 AM |
| Zacks: Brokerages Expect Obalon Therapeutics Inc (OBLN) Will Post Quarterly Sales of $3.88 Million
www.americanbankingnews.com - March 6 at 7:56 AM |
| Obalon Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 5 at 4:49 PM |
| Obalon Schedules Fourth Quarter and Year End 2017 Financial Results Conference Call for March 5, 2018 at 5:00 p.m. Eastern Time
finance.yahoo.com - March 5 at 9:59 AM |
| Robbins Arroyo LLP: Obalon Therapeutics, Inc. (OBLN) Misled Shareholders According to a Recently Filed Lawsuit
finance.yahoo.com - March 3 at 9:39 AM |
| Obalon Therapeutics, Inc. Reminder: Important April 16, 2018 Lead Plaintiff Deadline in Class Action- OBLN
finance.yahoo.com - March 2 at 4:53 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Obalon Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OBLN
finance.yahoo.com - March 1 at 9:22 AM |
Obalon Therapeutics (NASDAQ:OBLN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Obalon Therapeutics (NASDAQ:OBLN) Income Statement, Balance Sheet and Cash Flow Statement
Obalon Therapeutics (NASDAQ OBLN) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
